Alaunos Therapeutics, Inc.·4

Apr 15, 8:42 PM ET

Postma Robert W 4

4 · Alaunos Therapeutics, Inc. · Filed Apr 15, 2025

Insider Transaction Report

Form 4
Period: 2025-04-11
Transactions
  • Award

    Common Stock

    2025-04-13$2.92/sh+20,804$60,74829,083 total
  • Purchase

    Series A-1 Convertible Preferred Stock

    2025-04-11$2.76/sh+500$1,380500 total(indirect: By WaterMill Asset Management Corp.)
    Exercise: $2.76From: 2025-04-11Common Stock (181,159 underlying)
Holdings
  • Common Stock

    (indirect: By WaterMill Asset Management Corp.)
    33,333
  • Common Stock

    (indirect: By Spouse)
    24
Footnotes (3)
  • [F1]The shares are directly held by WaterMill Asset Management Corp. ("WaterMill"). The Reporting Person serves as the principal of WaterMill.
  • [F2]The preferred stock is perpetual and therefore has no expiration date.
  • [F3]The reporting person disclaims beneficial ownership of these equity securities to the extent that after giving effect of the conversion of the preferred stock and the underlying common stock issuance, the reporting person would beneficially own in the aggregate in excess of 4.99% of the outstanding shares immediately after giving effect to such conversion or issuance.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4